Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Analysts are estimating that Amicus Therapeutics will report an earnings per share (EPS) of $0.08. The announcement from Amicus Therapeutics is eagerly anticipated, with investors seeking news of ...

Amicus Therapeutics (NASDAQ:FOLD) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $21.7 million in its first quarter. On a per-share basis, the Princeton, New Jersey-based ...

The FDA pushed back its decision date on Cytokinetics heart drug, while AstraZeneca got Phase 3 trial results that could help ...

Investing.com -- Amicus Therapeutics (NASDAQ:FOLD) reported first-quarter 2025 earnings that beat analyst expectations, but revenue fell short, sending shares plummeting 11.3% in early trading.

Dimerix (ASX: DXB), an Australian drug developer, has entered into an exclusive US licensing agreement with Amicus ...

Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Amicus ...

Amicus Therapeutics reported a larger-than-expected loss for Q1 2025, with earnings per share (EPS) at -$0.16, missing the forecast of -$0.02. The company’s revenue also fell short of ...

MELBOURNE, Australia and PRINCETON, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Dimerix Limited (ASX: DXB, “Dimerix”) and Amicus Therapeutics (Nasdaq: FOLD ...